Tag: Home infusion drugs
Short takes: BioScrip, BOC, Mediware, NASP
February 8, 2017HME News Staff
BioScrip has joined Keep My Infusion Care at Home, a coalition formed in response to a change in the payment model for Medicare Part B home infusion drugs. The Denver-based BioScrip is a leading provider of infusion and home care management solutions�Staff members of the Board of Certification and Accreditation (BOC)are finalists for two Stevie Awards: Front-Line Customer Service Team of the Year and Business Development Professional of the Year. Finalists were chosen from more than 2,300...
BioScrip restructures credit
December 14, 2016HME News Staff
DENVER - BioScrip has announced a plan to increase its liquidity.
The home infusion and home care provider has proposed an amendment to its original credit agreement that would restructure an existing revolving credit facility, providing immediate access to $15 million.
BioScrip has suffered losses in recent quarters. Net revenues for the third quarter of 2016 were $224.5 million, a decrease of 9.2% from a year ago. Net losses from continuing operations were $11.1 million vs. $24.5 million.
The...
OIG spotlights home infusion payments in report to Congress
December 2, 2015HME News Staff
WASHINGTON - Medicare could have reduced payments for home infusion drugs by $251 million over an18-month period if it used an average sales price methodology, the Office of Inspector General said in its Semiannual Report to Congress. The OIG, which has recommended that Medicare switch from an average wholesale price to an ASP model, found that “at least 42% of DME infusion drugs had Medicare payment amounts that were more than twice their estimated acquisition costs.” The OIG reported...
Will CMS add home infusion drugs to bid program?
February 21, 2013HME News Staff
WASHINGTON - The Office of Inspector General (OIG) recommends in a new study that CMS change the way it pays for home infusion drugs.One of the options laid out by the OIG: Include home infusion drugs in the next round of competitive bidding. While external infusion pumps and supplies were included in the Round 1 re-compete (but not Round 1 or Round 2), CMS has not included drugs at all. CMS concurred with this recommendation.The second option: Seek a legislative change requiring home infusion drugs...